TRAIL/Apo-2L: Mechanisms and clinical applications in cancer

Neoplasia

Volumn 3, Issue 6, 2001, Pages 535-546

  Srivastava, R K ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

Apoptosis; Caspase; Death receptor; IAP; Mitochondria; TRAIL

Indexed keywords

CASPASE 8; CASPASE 9; FAS ANTIGEN; MEMBRANE RECEPTOR; PROTEIN BCL 2; PROTEIN BCL X; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER RADIOTHERAPY; CANCER THERAPY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; LIVER TOXICITY; LYMPHOID CELL; MITOCHONDRION; NATURAL KILLER CELL; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; XENOGRAFT;

EID: 0035216008     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900203     Document Type: Article

References (145)

1. Human ICE/CED-3 protease nomenclature
2. Death receptors: Signaling and modulation
3. Safety and antitumor activity of recombinant soluble Apo2 ligand
4. NF-kappa B: Ten years after
5. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: Implications for TNF receptor activation
6. TRAIL receptor-2 signals apoptosis through FADD and caspase-8
7. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL
8. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization
9. Regulation of cell death protease caspase-9 by phosphorylation
10. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling
11. Death receptor 5 a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway
12. Constitutively active Akt in prostate cancer cells directly correlates with cellular survival and resistance to TRAIL
13. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy
14. Control of programmed cell death by the baculovirus genes p35 and iap
15. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif
16. To die or not to die - The quest of the TRAIL receptors
17. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
18. Cloning and characterization of TRAIL-R3 a novel member of the emerging TRAIL receptor family
19. Mitochondria as the central control point of apoptosis
20. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases
21. X-linked IAP is a direct inhibitor of cell-death proteases
22. Mechanisms and consequences of activation of protein kinase B/Akt
23. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating JAP inhibition
24. Human IAP-like protein regulates programmed cell death downstream of Bcl-xL and cytochrome c
25. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors
26. A sequential treatment regimen with melatonin and all-trans retinoic acid induces apoptosis in MCF-7 tumour cells
27. Caspase inhibitors
28. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily
29. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
30. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
31. The TRAIL to selective tumor death
32. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL
33. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11
34. Cell death: TRAIL and its receptors
35. Is TRAIL hepatotoxic?
36. Apoptotic pathways: The roads to ruin
37. Mitochondria and apoptosis
38. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
39. TRAIL: A molecule with multiple receptors and control mechanisms
40. Functional analysis of TRAIL receptors using monoclonal antibodies
41. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine
42. Caspase cleaved BID targets mitochondria and is required for cytochrome c release while Bcl-XL prevents this release but not tumor necrosis factor-R1/Fas death
43. Cif (cytochrome c efflux-inducing factor) activity is regulated by Bcl-2 and caspases and correlates with the activation of Bid
44. Characterization of XIAP-deficient mice
45. Expression of baculovirus P35 prevents cell death in Drosophila
46. Fas triggers ar alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule
47. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways
48. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
49. Inhibition of death receptor signals by cellular FLIP
50. Chromosome 10 alterations in prostate adenocarcinoma (review)
51. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis -inducing ligand
52. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade
53. FADD is required for multiple signaling events downstream of the receptor Fas
54. Bax directly induces release of cytochrome c from isolated mitochondria
55. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation
56. 2 A crystal structure of an extracellular fragment of human CD40 ligand [published erratum appears in Structure 1995 Dec 15;3(12):1426]
57. DNA damaging agents induceexpression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1
58. Type I Interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs
59. Involvement of TNF-related apoptosis-inducing ligand in human CD4 + T cell-mediated cytotoxicity
60. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells
61. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
62. Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis
63. Expression of TRAIL (Apo2L), DR4 (TRAIL receptor 1), DR5 (TRAIL receptor 2) and TRID (TRAIL receptor 3) genes in multidrug resistant human acute myeloid leukemia cell lines that overexpress MDR 1 (HL60/Tax) or MRP (HL60/AR)
64. Failure of bcl-2 to block mitochondrial dysfunction during TRAIL-induced apoptosis
65. Molecular determinants of response to TRAIL in killing of normal and cancer cells
66. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
67. The CD95(Apo-1/Fas)/CD95L system
68. CD95 (Apo-1/Fas)-mediated apoptosis: Live and let die
69. The mitochondrial death/life regulator in apoptosis and necrosis
70. FADD is required for DR4- and DR5-mediated apoptosis: Lack of trail -induced apoptosis in FADD-deficient mouse embryonic fibroblasts
71. The inhibitors of apoptosis (IAPs) and their emerging role in cancer
72. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
73. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes
74. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis
75. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
76. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
77. Identification of XAF1 as an antagonist of XIAP anti-Caspase activity
78. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes
79. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors
80. A novel receptor for Apo2L/TRAIL contains a truncated death domain
81. A GTP-binding adapter protein couples TRAIL receptors to apoptosis-inducing proteins
82. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin
83. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2
84. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis
85. From bench to clinic with apoptosis-based therapeutic agents
86. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels
87. Human brain-cell death induced by tumournecrosis-factor-related apoptosis-inducing ligand (TRAIL)
88. Extensive lymphopenia due to apoptosis of uninfected lymphocytes in acute measles patients
89. Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells
90. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand
91. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
92. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling
93. The receptor for the cytotoxic ligand TRAIL
94. Mechanisms of CD95 (Apo-1/Fas)-mediated apoptosis
95. The death receptors
96. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
97. Avoiding premature apoptosis of normal epidermal cells
98. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB
99. Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis
100. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins
101. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases
102. Characterization of two receptors for TRAIL
103. Apoptosis signaling by death receptors
104. TRICK2 a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL
105. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells
106. P53-dependent and independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha
107. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
108. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7
109. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations
110. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2
111. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization
112. Intracellular mechanisms of TRAIL and its role in cancer therapy
113. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis
114. Bcl-2-mediated drug resistance: Inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription
115. Bcl-2 and Bcl-X(L) block thapsigargin-induced nitric oxide generation, c-Jun NH(2)-terminal kinase activity, and apoptosis
116. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
117. Intracellular mechanisms of TRAIL: Apoptosis through mitochondrial-dependent and -independent pathways
118. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6
119. Overexpression of BCL2 blocks TNF-related apoptosisinducing ligand (TRAIL)-induced apoptosis in human lung cancer cells
120. Molecular characterization of mitochondrial apoptosis-inducing factor
121. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs
122. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes
123. Pro-survival function of Akt/PKB in prostate cancer cells: Relationship with TRAIL resistance
124. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells
125. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor
126. Conservation of baculovirus inhibitor of apoptosis repeat proteins (BIRPs) in viruses, nematodes, vertebrates and yeasts
127. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins
128. Rel/NF-kappa B/I kappa B family: Intimate tales of association and dissociation
129. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts
130. Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD)
131. Dominant-negative FADD inhibits TNFR60-, Fas/Apo1- and TRAIL-R/Apo2-mediated cell death but not gene induction
132. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells
133. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL
134. The CD95 (Apo-1/Fas) and the TRAIL (APO-2L) apoptosis systems
135. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
136. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II
137. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression
138. Identification and characterization of a new member of the TNF family that induces apoptosis
139. Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation
140. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
141. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis
142. Bid-deficient mice are resistant to Fasinduced hepatocellular apoptosis
143. Natural killer (NK) cell-mediated cytotoxicity: Differential use of TRAIL and Fas ligand by immature and mature primary human NK cells
144. TNF-related apoptosisinducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis
145. Apaf1, a human protein homologous to C elegans CED-4, participates in cytochrome c-dependent activation of caspase-3